This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAF), Tarsus Pharmaceuticals (TARS) and enGene Holdings (ENGN)

Tipranks - Tipranks - Fri Apr 3, 6:10AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alterity Therapeutics (PRNAF), Tarsus Pharmaceuticals (TARS) and enGene Holdings (ENGN) with bullish sentiments.

End of Quarter Sale - 50% Off TipRanks

Alterity Therapeutics (PRNAF)

Canaccord Genuity analyst Madeleine Williams maintained a Buy rating on Alterity Therapeutics on March 30 and set a price target of A$0.01.

According to TipRanks.com, Williams has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.1% and a 25.6% success rate. Williams covers the Healthcare sector, focusing on stocks such as Neuren Pharmaceuticals Limited, Clinuvel Pharmaceuticals, and Pro Medicus Limited. ;'>

Currently, the analyst consensus on Alterity Therapeutics is a Moderate Buy with an average price target of $0.01.

See Insiders’ Hot Stocks on TipRanks >>

Tarsus Pharmaceuticals (TARS)

In a report released yesterday, Eddie Hickman from Guggenheim maintained a Buy rating on Tarsus Pharmaceuticals, with a price target of $90.00. The company’s shares closed last Wednesday at $70.22.

According to TipRanks.com, Hickman is a 4-star analyst with an average return of 21.0% and a 58.8% success rate. Hickman covers the Healthcare sector, focusing on stocks such as ProMIS Neurosciences, Zevra Therapeutics, and Atai Beckley N.V. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tarsus Pharmaceuticals with a $89.67 average price target, a 27.4% upside from current levels. In a report issued on March 21, LifeSci Capital also maintained a Buy rating on the stock with a $95.00 price target.

enGene Holdings (ENGN)

Wells Fargo analyst Yanan Zhu maintained a Buy rating on enGene Holdings today and set a price target of $25.00. The company’s shares closed last Wednesday at $6.76.

According to TipRanks.com, Zhu is a 5-star analyst with an average return of 14.6% and a 38.0% success rate. Zhu covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Atrium Therapeutics, Inc., and Iovance Biotherapeutics. ;'>

Currently, the analyst consensus on enGene Holdings is a Strong Buy with an average price target of $24.00, which is a 246.3% upside from current levels. In a report issued on March 26, Piper Sandler also maintained a Buy rating on the stock.

Read More on PRNAF:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).